Spyre Therapeutics, Inc. 8-K

What Happened
Spyre Therapeutics, Inc. announced that at its Annual Meeting on May 27, 2026, stockholders approved the Amended and Restated 2016 Employee Stock Purchase Plan (AR ESPP). The AR ESPP’s material features are described in Proposal 4 of the company’s definitive proxy statement filed April 10, 2026, and the full plan text is filed as Exhibit 10.1 to the Form 8‑K (filed May 29, 2026). Also effective May 27, 2026, director Peter Harwin resigned from the Board; his resignation was not due to any disagreement with the company, and the Board size was reduced from eight to seven directors.

Key Details

• Annual Meeting held May 27, 2026; Form 8‑K filed May 29, 2026.
• AR ESPP approved by stockholders; plan description in the April 10, 2026 proxy (Proposal 4) and plan text filed as Exhibit 10.1.
• Director Peter Harwin resigned effective May 27, 2026; resignation not due to disagreement with the company.
• Board size reduced from eight directors to seven.

Why It Matters
Approval of the AR ESPP means Spyre has shareholder authorization for its updated employee stock purchase plan; investors should review Proposal 4 of the 2026 Proxy Statement and Exhibit 10.1 for the plan’s terms (including share allocation and purchase mechanics). The board change is limited to one director resignation with no dispute reported. Both items are governance matters that shareholders and prospective investors may consider when evaluating company oversight and employee equity programs.